Contact
searchSearch
HMP Global
Login

News

News
Gilteritinib Fails to Improve Overall Survival in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
06/16/2026
Emily Estrada
Results from the phase 3 HOVON156/AMLSG28-18/PASHA trial demonstrated that gilteritinib did not significantly improve overall survival compared with midostaurin when combined with intensive chemotherapy in patients with newly diagnosed...
Results from the phase 3 HOVON156/AMLSG28-18/PASHA trial demonstrated that gilteritinib did not significantly improve overall survival compared with midostaurin when combined with intensive chemotherapy in patients with newly diagnosed...
Results from the phase 3...
06/16/2026
Oncology
News
Switchable Allogeneic CAR T-Cell Therapy Shows Early Promise in Relapsed or Refractory Acute Myeloid Leukemia
06/16/2026
Emily Estrada
Results from the phase 1a RevSTAR-123 study demonstrated that an investigational switchable allogeneic CD123-directed CAR T-cell therapy showed encouraging clinical activity in heavily pretreated relapsed or refractory acute myeloid leukemia.
Results from the phase 1a RevSTAR-123 study demonstrated that an investigational switchable allogeneic CD123-directed CAR T-cell therapy showed encouraging clinical activity in heavily pretreated relapsed or refractory acute myeloid leukemia.
Results from the phase 1a...
06/16/2026
Oncology
News
Switchable Allogeneic CAR T-Cell Therapy Shows Early Promise in Relapsed or Refractory Acute Myeloid Leukemia
06/16/2026
Emily Estrada
Results from the phase 1a RevSTAR-123 study demonstrated that an investigational switchable allogeneic CD123-directed CAR T-cell therapy showed encouraging clinical activity in heavily pretreated relapsed or refractory acute myeloid leukemia.
Results from the phase 1a RevSTAR-123 study demonstrated that an investigational switchable allogeneic CD123-directed CAR T-cell therapy showed encouraging clinical activity in heavily pretreated relapsed or refractory acute myeloid leukemia.
Results from the phase 1a...
06/16/2026
Oncology
News
Total Marrow and Lymphoid Irradiation Shows Promise Prior to alloHCT in Relapsed or Refractory Acute Leukemia
06/15/2026
Emily Estrada
Total marrow and lymphoid irradiation combined with high-dose etoposide and cyclophosphamide was feasible and associated with encouraging outcomes in patients with relapsed or refractory acute leukemia undergoing alloHCT, as demonstrated by...
Total marrow and lymphoid irradiation combined with high-dose etoposide and cyclophosphamide was feasible and associated with encouraging outcomes in patients with relapsed or refractory acute leukemia undergoing alloHCT, as demonstrated by...
Total marrow and lymphoid...
06/15/2026
Oncology
News
KITE-222 Demonstrates Manageable Safety but Limited Clinical Activity in Relapsed or Refractory Acute Myeloid Leukemia
06/10/2026
Stephanie Holland
Results from a phase 1 dose-escalation trial demonstrated that KITE-222, an autologous CLL-1-directed CAR T-cell therapy, demonstrated a manageable safety profile but limited clinical activity in patients with relapsed or refractory acute...
Results from a phase 1 dose-escalation trial demonstrated that KITE-222, an autologous CLL-1-directed CAR T-cell therapy, demonstrated a manageable safety profile but limited clinical activity in patients with relapsed or refractory acute...
Results from a phase 1...
06/10/2026
Oncology
FDA Approval
FDA Approves Oral Decitabine and Cedazuridine Plus Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
05/13/2026
Janelle Bradley
The FDA granted approval to the first fully oral regimen of decitabine and cedazuridine plus venetoclax for adults with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
The FDA granted approval to the first fully oral regimen of decitabine and cedazuridine plus venetoclax for adults with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
The FDA granted approval to the...
05/13/2026
Oncology
News
Ruxolitinib Plus Venetoclax Demonstrates Favorable Safety and Modest Clinical Activity in Relapsed or Refractory Acute Myeloid Leukemia
03/31/2026
Emily Estrada
Results from a multicenter phase 1 trial demonstrated that ruxolitinib plus venetoclax was well tolerated and produced modest clinical activity in heavily pretreated adults with relapsed or refractory acute myeloid leukemia, while exploratory...
Results from a multicenter phase 1 trial demonstrated that ruxolitinib plus venetoclax was well tolerated and produced modest clinical activity in heavily pretreated adults with relapsed or refractory acute myeloid leukemia, while exploratory...
Results from a multicenter phase...
03/31/2026
Oncology
News
Dapolsertib Demonstrates Favorable Safety and Modest Clinical Activity in Relapsed/Refractory Acute Myeloid Leukemia
03/02/2026
Emily Estrada
Results from the phase 1/2 DIAMOND-01 study demonstrated that dapolsertib, a first-in-class dual PIM and FLT3 kinase inhibitor, was well tolerated but demonstrated modest single-agent activity in heavily pretreated patients with relapsed or...
Results from the phase 1/2 DIAMOND-01 study demonstrated that dapolsertib, a first-in-class dual PIM and FLT3 kinase inhibitor, was well tolerated but demonstrated modest single-agent activity in heavily pretreated patients with relapsed or...
Results from the phase 1/2...
03/02/2026
Oncology
Ira Zackon, MD
Videos
Real-World Analysis Finds Venetoclax-Based Induction Effective for Very Elderly Patients With Acute Myeloid Leukemia
03/02/2026
Ira Zackon, MD
Ira Zackon, MD, shared results from a large real-world analysis which found venetoclax plus a hypomethylating agent is a feasible and effective therapeutic option for patients with AML aged 70 years and older.
Ira Zackon, MD, shared results from a large real-world analysis which found venetoclax plus a hypomethylating agent is a feasible and effective therapeutic option for patients with AML aged 70 years and older.
Ira Zackon, MD, shared results...
03/02/2026
Oncology
Ibrahim Aldoss, MD
Videos
Azacitidine Plus Venetoclax Shows Superior Efficacy Compared With Intensive Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia
01/12/2026
Ibrahim Aldoss, MD
Ibrahim Aldoss, MD, shared results from the phase 2 PARADIGM trial which showed frontline azacitidine plus venetoclax significantly improved survival, response rates, and quality of life compared with intensive chemotherapy for AML.
Ibrahim Aldoss, MD, shared results from the phase 2 PARADIGM trial which showed frontline azacitidine plus venetoclax significantly improved survival, response rates, and quality of life compared with intensive chemotherapy for AML.
Ibrahim Aldoss, MD, shared...
01/12/2026
Oncology

Recent News

News
NCCN Recommends Rusfertide as Category 1 Option Across Low- and High-Risk Polycythemia Vera
09/22/2026
Stephanie Holland
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines...
09/22/2026
Oncology
News
FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes
09/22/2026
Emily Estrada
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track...
09/22/2026
Oncology
News
Trastuzumab Deruxtecan Reduces Risk of Progression or Death in First-Line HER2-Mutant Non-Small Cell Lung Cancer
09/22/2026
Stephanie Holland
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3...
09/22/2026
Oncology
News
Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
09/21/2026
Emily Estrada
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3...
09/21/2026
Oncology
FDA Approval
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer
09/18/2026
Stephanie Holland
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase...
09/18/2026
Oncology
FDA Alerts
FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer
09/17/2026
Emily Estrada
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental...
09/17/2026
Oncology
News
Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma
09/17/2026
Emily Estrada
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE...
09/17/2026
Oncology
News
Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation
09/17/2026
Emily Estrada
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial...
09/17/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer
09/16/2026
Stephanie Holland
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3...
09/16/2026
Oncology
FDA Alerts
FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access
09/16/2026
Stephanie Holland
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing...
09/16/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use